The announcement builds on AZ's announcement earlier this year that it will invest $2.5 billion in an R&D facility in China, ...

EVERSANA, a leading provider of global commercial services to the life sciences industry, has announced two strategic ...

At ASCO 2025, ImmunityBio’s chief medical officer, Dr Sandeep Reddy, spoke with pharmaphorum about the importance of FDA ...

While Takeda's Qdenga (TAK-003) shot is approved as a two-dose regimen to protect people from the disease in dozens of ...

US Senators Bernie Sanders and Angus King have introduced a bill that seeks to ban direct-to-consumer (DTC) advertising by ...

The Health and Human Services (HHS) Secretary named eight hand-picked members of the Advisory Committee on Immunisation ...

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...

A fourth revolution in cancer care is taking shape, one that steps away from the current well-trodden path. This revolution ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

Describing the current treatment landscape for primary and secondary bone cancer, Romness explains the potential of their own ...

Alpha-1 is a microcosm of the rare disease world. The challenges we face, late diagnoses, inconsistent care, and unaffordable ...

Currently available PCSK9-targeting therapies are Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab), ...